MDS | Tumor

CURE’s myelodysplastic syndrome (MDS) page is an extensive resource of cancer information featuring the latest myelodysplastic syndrome news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on MDS.

Cancer is Hard Enough Without Infections

February 21st 2025, 6:00pm

Article

As a cancer survivor, I describe battling both cancer and infections and the toll it takes on my body.

Moving Slower and Slower After Myelodysplastic Syndrome

February 12th 2025, 6:00pm

Article

I have been frustrated lately by my increasing slowness following an blood cancer diagnosis, which has become noticeable to others.

Breaking Down Cancer Therapies Approved by the FDA in January 2025

February 3rd 2025, 4:00pm

Article

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations like AML, MDS and breast cancer.

A Phase 1 Trial of Iadademstat Plus Vidaza Has Dosed a Patient With MDS

January 29th 2025, 10:00pm

Article

The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with myelodysplastic syndrome.

Life After MDS and Accomplishing Your Goals

January 28th 2025, 6:00pm

Article

After a long and difficult journey, I finally published the book I set out to write as my legacy, overcoming cancer and the challenges of deafness.

FDA Approves GRAFAPEX/Fludarabine Before alloHSCT in AML and MDS

January 24th 2025, 4:15pm

Article

The FDA has approved GRAFAPEX™ and fludarabine as a preparative regimen in acute myeloid leukemia or myelodysplastic syndrome prior to alloHSCT.

Cancer Taught Me to Make the Best of Everything

December 13th 2024, 6:00pm

Article

As a survivor of MDS, I’ve learned to make the best of every day and to be thankful for life. Sometimes this means avoiding others who are less grateful.

Venclexta Plus Mavenclad Boosts Response Rates in AML, MDS

December 10th 2024, 2:05pm

Article

The Venclexta-based regimen improved complete response rates in patients with acute myeloid leukemia and myelodysplastic syndromes.

Smoking May Be Linked With Genetic Mutations, Progression Risk in MDS

December 7th 2024, 7:28pm

Article

Results from the study also showed the potential association between smoking, disease progression and survival in patients with myelodysplastic syndromes.

FDA Grants Fast Track Designation to R289 in Lower-Risk MDS

December 5th 2024, 2:00pm

Article

The novel treatment is being evaluated for patients with previously treated transfusion-dependent lower-risk myelodysplastic syndrome.